New TB vaccine under trial in South Africa promises hope for millions

A new TB vaccine trial in South Africa offers hope for curbing the global TB epidemic, with promising results for adolescents and adults, VOA reported in a video yesterday.

The M72 vaccine trial targets latent TB, preventing its activation in immunocompromised individuals like HIV/AIDS patients, showing promise in reducing TB transmission.

It has shown efficacy rates of 50%, meaning 8.5 million lives can be saved and 76 million new cases can be prevented, the source mentioned citing WHO authorities.

The TB vaccine results will be out in 5 years, and if proven successful, the roll-out is expected to begin by 2030.